Considering that human ureter is the optimal model for ureter pharmacology, Piezo1 and TRPV2 channels may present promising pharmacological targets to improve ureteral stone passage as well as treatment of stent-associated symptoms. The gene discussed is TRPV2; the disease is ureterolithiasis.